BioStem Technologies Inc. Announces Issuance of Drug Enforcement Administration Registration for Qualified Pharma Ingredients

June 18, 2018

 

Pompano Beach, FL, June 18, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, has completed its facility inspection for its repackaging subsidiary, Qualified Pharma Ingredients Inc, and has been issued a DEA registration for Controlled Substances Schedule III-V, obtaining capabilities in controlled substances and further expanding its marketable product lines.

 

As Qualified Pharma Ingredients Inc (“QPI, Inc.”) continues to expand its potential revenue streams, this registration allows QPI to carry an even greater number of active pharmaceutical ingredients to be sold to compounding pharmacies within the domestic market.

 

Larry Jones, BioStem’s Chief Revenue Officer, said, “Our team at QPI is very excited about receiving our DEA registration. Our team is committed to having a robust product portfolio that can meet the needs of the market, and we are proud to be making these additions to our product line-up.”

 

About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.

 

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

 

BioStem Technologies, Inc.

Phone: 954-380-8342

Website: http://www.QPIRX.com  http://www.biostemtech.com

Email: info@biostemtech.com

Twitter: @Biostemtech

Facebook: BioStem Technologies

 

Investor Relations:

Andrew Van Vurst

info@biostemtech.com

(954) 380-8342

Share on Facebook
Share on Twitter
Please reload

Featured Posts

BioStem Technologies Releases Third Quarter 2018 Shareholder Update

December 10, 2018

1/2
Please reload

Recent Posts
Please reload

Archive